Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 316 to 330 of 1300 results for heart OR cardi* OR arrythmia

  1. Sternal Talon for sternal closure in cardiothoracic surgery (MIB88)

    NICE has developed a medtech innovation briefing (MIB) on the Sternal Talon for sternal closure in cardiothoracic surgery .

  2. Psoriasis (QS40)

    This quality standard covers assessing and managing psoriasis in adults, young people and children. It describes high-quality care in priority areas for improvement.

  3. Diabetes: admission rates (angina) (IND41)

    This indicator covers admission rates due to angina in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG59

  4. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab (Simponi), tocilizumab (RoActemra) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried conventional DMARDs only but they have not worked.

  5. Smoking: support and treatment for people with bipolar, schizophrenia and other psychoses (IND155)

    This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder or other psychoses who are recorded as current smokers who have a record of an offer of support and treatment within the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM125

  6. Coronary sinus narrowing device implantation for refractory angina (IPG712)

    Evidence-based recommendations on coronary sinus narrowing device implantation for refractory angina in adults. This involves putting a device into the coronary sinus to narrow it with the aim of improving the flow of oxygenated blood throughout the heart muscle.

  7. Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379

    In development Reference number: GID-TA11429 Expected publication date:  09 September 2026

  8. KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication: early value assessment (HTG694)

    Early value assessment (EVA) guidance on KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication.

  9. Extra corporeal membrane oxygenation for acute heart failure in children

    Discontinued Reference number: GID-IP1153

  10. Percutaneous laser therapy for fetal tumours (IPG180)

    Evidence-based recommendations on percutaneous laser therapy for fetal tumours. This involves inserting a needle through the mother's abdomen to the tumour and using laser energy to shrink it.

  11. Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome (HTG735)

    Evidence-based recommendations on home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome.

  12. Smoking: smoking status of people with bipolar, schizophrenia and other psychoses (IND154)

    This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM124

  13. Lifelight First for monitoring vital signs (MIB213)

    NICE has developed a medtech innovation briefing (MIB) on Lifelight First for monitoring vital signs .

  14. Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)

    This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18. The guideline recommends how to support children and young people and their families and carers to maintain tight control of blood glucose to reduce the long-term risks associated with diabetes.